UNSPSC 51191581: Theobromine magnesium oleate

This classification denotes a bronchodilator C18H33O2.C7H7N4O2.Mg, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3L7IL2RTM6, chemically known as magnesium 3,7-dimethylxanthine oleate, but more generally known as theobromine magnesium oleate, which bears US NIH Compound Identifier 57352542. European Medicines Agency schedules Theobromine magnesium oleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15513MIG.

Most nations, for tariff and trade purposes, schedule theobromine magnesium oleate under HS 29399990 and SITC 54149. As of Q4 2014, THEOBROMINE MAGNESIUM OLEATE remains US FDA's Preferred Term for this commodity. SMILES: CCCCCCCC/C=C\CCCCCCCC(=O)[O-].CN1CNC2C1C(=O)[N-]C(=O)N2C.[MG+2].

UNSPSC 51191581 Theobromine magnesium oleate is a Commodity code that captures chemical and pharmaceutical supply for state and local government operations, though recent sourcing activity shows limited direct procurement of theobromine magnesium oleate itself. Instead, state and local buyers under related chemical and pharmaceutical codes are soliciting sodium bisulfite for water treatment, generic pharmaceuticals and over-the-counter products for health and human services facilities, and related specialty chemicals. The issuing bodies include municipal utilities (water pollution control facilities), state health and human services networks, and cooperative purchasing alliances serving multiple jurisdictions and states.

The City of Meriden, Connecticut issued an IFB (B027-15) for sodium bisulfite chemical supply to its Water Pollution Control Facility with bids due July 29, 2026, requiring $1,000,000 to $2,000,000 General Liability coverage and performance and payment bonds. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) on January 20, 2026 with a March 26, 2026 due date to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities including Oregon, with awarded vendors effective July 1, 2026 and requiring $5,000,000 commercial general liability coverage and compliance with cGMP and FDA requirements. Activity under this code spans Connecticut and the Upper Midwest through cooperative purchasing vehicles and individual municipal procurement.